announced that the Data Monitoring Committee (DMC) has reviewed the open-label arm of its Phase 3 sunRIZE study for the treatment of congenital hyperinsulinism with ersodetug in infants under one ...
Open-label arm (infant participants DMC approved enrollment of infants into the double-blind portion of the study sunRIZE enrollment completion expected in Q2 2025, subject to outcomes from upcoming ...
This is shown by the largest survey ... Infant Mortality Rates Declining, but Sudden Unexpected Infant Death Is on the Rise Jan. 27, 2025 — Infant mortality in the United States decreased by 24. ...
Q: My baby is small but my pediatric provider says she is "following the curve" so he is not worried. What does that mean? I'm still worried! A. If your baby is "following the curve" of the growth ...
Neonatal skin antisepsis with alcohol-based compared to aqueous 2% chlorhexidine, used in moderate preterm infants or extremely preterm infants after the first week of life, is safe and may be ...
It mainly affects infants and children – putting them ... unmet medical need for newborns and children with congenital hyperinsulinism who have either no or very limited treatment options ...
Service specifications are important in clearly defining the standards of care expected from organisations funded by NHS England to provide specialised care. The specifications have been developed by ...